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OBJECTIVE — To evaluate the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin in drug-
naïve patients with inadequately controlled type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Thisdouble-blind,placebo-controlled,mul-
ticenter study included 329 patients with poorly controlled diabetes randomized to once-daily
treatment with 12.5 mg alogliptin (n  133), 25 mg alogliptin (n  131), or placebo (n  65)
for26weeks.PrimaryefﬁcacyendpointwasmeanchangefrombaselineinA1Cattheﬁnalvisit.
RESULTS — At week 26, mean change in A1C was signiﬁcantly greater (P  0.001) for 12.5
mg (0.56%) and 25 mg (0.59%) alogliptin than placebo (0.02%). Reductions in fasting
plasma glucose were also greater (P  0.001) in alogliptin-treated patients than in those receiv-
ing placebo. Overall, incidences of adverse events (67.4–70.3%) and hypoglycemia (1.5–3.0%)
were similar across treatment groups.
CONCLUSIONS — Alogliptin monotherapy was well tolerated and signiﬁcantly improved
glycemiccontrolinpatientswithtype2diabetes,withoutraisingtheincidenceofhypoglycemia.
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I
nhibition of dipeptidyl peptidase-4
(DPP-4) increases the concentration of
glucagon-like peptide-1, an incretin
hormone that stimulates glucose-
dependent insulin release, suppresses
glucagon production, slows gastric emp-
tying, reduces appetite, and may promote
preservation of -cell function in patients
with type 2 diabetes (1). Alogliptin is a
novel, high-afﬁnity, high-speciﬁcity
DPP-4 inhibitor that produces rapid and
sustained DPP-4 inhibition and signiﬁ-
cantly reduces postprandial plasma glu-
cose concentrations in patients with type
2 diabetes (2,3). A phase-three study was
conducted to evaluate the efﬁcacy and
safety of alogliptin in adults with type 2
diabetes that was inadequately controlled
with diet and exercise.
RESEARCH DESIGN AND
METHODS— Eligible patients were
treatment-naïve (i.e., no current antidia-
betes therapy and 7 days of therapy in
thepast3months)menandwomen,aged
18–80 years, with type 2 diabetes. Key
inclusion criteria included A1C 7–10%,
BMI 23–45 kg/m
2, treatment with diet
and exercise for 1 month, and systolic/
diastolic blood pressure 180/110
mmHg. Patients received counseling on
dietandexercise.Patientswhocompleted
a 4-week, single-blind run-in period with
fasting plasma glucose (FPG) 275
mg/ml (15.27 mmol/l) and 75% com-
pliance (by tablet count) were random-
ized (2:2:1) to 26 weeks of double-blind
treatment with 12.5 mg alogliptin, 25 mg
alogliptin,orplacebotakenoncedailybe-
foretheﬁrstmeal.Additionalantidiabetes
agents were prohibited.
Efﬁcacy assessments included all ran-
domized patients who received the dou-
ble-blind study drug. The primary end
point was mean change from baseline in
A1C at week 26. Other efﬁcacy measures
included changes in FPG, clinical re-
sponserates,incidencesofmarkedhyper-
glycemia (FPG 200 mg/dl [11.10
mmol/l]) and hyperglycemic rescue, and
changes in body weight. Exploratory end
points included changes in measures of
pancreatic function (fasting insulin, fast-
ing proinsulin, and homeostasis model
assessment of -cell function) and lipid
proﬁles. Treatment group differences for
the primary end point were analyzed
through ANCOVA, with treatment and
geographic region as variables and base-
line A1C and diabetes duration as covari-
ates. The last observation carried forward
method was used for imputing missing
data; testing was two-sided at a signiﬁ-
cance level of 0.05. Continuous second-
ary efﬁcacy analyses were performed as
for the primary analysis, except that the
baseline covariate corresponds with the
testedendpoint.Incidencevariableswere
compared using nonparametric, ex-
tended Mantel-Haenszel X
2 tests; covari-
ates were the same as for the primary end
point.
The safety population included pa-
tients who took at least one dose of the
study drug (double blind). Safety assess-
ments included adverse events, clinical
laboratory ﬁndings, 12-lead electrocar-
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ings, vital signs, and hypoglycemic
events. Skin and digits were speciﬁcally
examined because of lesions previously
observed in monkeys given DPP-4 inhib-
itors other than alogliptin (4–6). Safety
ﬁndings were summarized with descrip-
tive statistics.
RESULTS— Of 420 patients enrolled
(see online appendix, available at http://
dx.doi.org/10.2337/dc08-1035), 329
were randomized to double-blind treat-
ment. Baseline characteristics were simi-
lar among treatment groups. Participants
hadameanSDageof53.411.1years
and baseline A1C 7.9  0.08% and were
predominantly male (53.2%) and white
(66.9%).
Mean A1C decreased signiﬁcantly
more with 12.5 mg (0.56%;P0.001)
or 25 mg (0.59%;P0.001) alogliptin
than with placebo (0.02%) by week 26.
SigniﬁcantA1Creductionswereobserved
as early as week 4 (P  0.001). FPG re-
ductions were signiﬁcantly greater with
alogliptin than with placebo at week 26
(P  0.001) and as early as week 1 (P 
0.002). The percentage of patients who
required hyperglycemic rescue was sig-
niﬁcantly less with alogliptin (12.5 mg,
9.8%;25mg,7.6%;P0.001)thanwith
placebo (29.7%). Minor reductions in
weight with alogliptin were neither clini-
callynorstatisticallysigniﬁcantrelativeto
placebo. Results for secondary efﬁcacy
measures and exploratory assessments
are summarized in Table 1.
Overall incidences of adverse events
(67.4–70.3%) and proportions of pa-
tients who discontinued because of ad-
verse events (1.5–2.3%) were similar
across treatment groups. Most adverse
eventsweremildormoderateinintensity.
Serious adverse events occurred without
relation to dose (12.5 mg, 3.8%; 25 mg,
0.8%; and placebo, 3.1%) and were con-
sidered unrelated to treatment. No pa-
tient died during the study. Adverse
eventsfromthemostcommonlyobserved
categories occurred with similar or lower
frequency in those given alogliptin versus
placebo (infection, 28.0–37.6%; gastro-
intestinal, 12.1–14.3%). Headache oc-
curred more frequently with alogliptin
(6.8–7.5%) than with placebo (4.7%).
Despite increased surveillance for skin-
related adverse events, their overall inci-
dence remained low (12.5%), albeit
higherwithalogliptin(12.8–15.2%)than
with placebo (6.3%), mostly because of
pruritic events. Two patients discontin-
ued because of skin-related adverse
events: one adverse event was considered
possiblyrelatedtothestudydrug(25mg,
moderate subcorneal pustular dermato-
sis);theotherwasjudgedunrelatedtothe
study drug (12.5 mg, moderate exacerba-
tion of contact dermatitis). No skin le-
sions resembling those noted in
nonclinical studies of other DPP-4 inhib-
itors were observed. Hypoglycemia was
rare (1.5–3.0%), and no hypoglycemic
event was considered an adverse event or
was severe enough to require assistance.
No clinically meaningful changes in labo-
ratory test results, vital sign measure-
ments, or electrocardiogram recordings
were observed.
CONCLUSIONS — Alogliptin mono-
therapy administered for 26 weeks to
treatment-naïve patients with type 2 dia-
betes produced signiﬁcant and clinically
meaningfulimprovementsinA1C.Glyce-
mic improvements with alogliptin were
rapid, sustained, and independent of age,
race, and sex. Alogliptin treatment was
welltoleratedandwasnotassociatedwith
treatment-related serious adverse events.
A low incidence of hypoglycemia oc-
curred with alogliptin and with placebo.
Weight gain is common among pa-
tients taking sulfonylureas and thiazo-
lidinediones and may reduce treatment
adherence(7,8);thus,theweightneutral-
ity of alogliptin and other DPP-4 inhibi-
tors may offer a therapeutic advantage
(9–15). Increases in the proinsulin-to-
insulin ratio with alogliptin versus pla-
cebo and a trend toward increased
homeostasis model assessment of -cell
function suggest that alogliptin, similarly
to other DPP-4 inhibitors (9–11,14,
15), may modestly improve pancreatic
function.
Insummary,theefﬁcacyandsafetyof
alogliptin monotherapy were comparable
with those of other DPP-4 inhibitors (9–
15). Alogliptin represents an effective
treatment option whether given alone or
in combination with antihyperglycemic
agents from other classes.
Table 1—Results of secondary efﬁcacy end points and exploratory assessments
Parameter Placebo
12.5 mg
Alogliptin P (vs. placebo) 25 mg Alogliptin P (vs. placebo)
n 64 133 — 131 —
A1C (%)
6.5% 7 (10.9) 23 (17.3) 0.818 27 (20.6) 0.294
7.0% 15 (23.4) 63 (47.4) 0.001 58 (44.3) 0.008
Reduction 0.5% 19 (29.7) 67 (50.4) 0.005 72 (55.0) 0.001
Reduction 1.0% 7 (10.9) 38 (28.6) 0.003 39 (29.8) 0.001
FPG 11.3  5.24 10.3  3.6 0.001 16.4  3.7 0.001
Hyperglycemic rescue 19 (29.7) 13 (9.8) 0.001 10 (7.6) 0.001
Marked hyperglycemia 30 (46.9) 44 (33.1) 0.110 33 (25.4) 0.005
Body weight (kg) 0.18  0.37 0.09  0.26 0.539 0.22  0.26 0.379
Proinsulin-to-insulin ratio 0.046  0.022 0.040  0.015 0.001 0.038  0.015 0.002
HOMA-B 0.26  5.98 7.53  3.99 0.279 9.70  4.08 0.172
Total cholesterol (mg/d)l 10.1  3.3 1.2  2.3 0.006 3.9  2.3 0.001
HDL cholesterol (mg/dl) 1.3  0.9 0.9  0.6 0.724 0.4  0.6 0.417
LDL cholesterol (mg/dl) 4.6  3.0 0.5  2.1 0.169 0.4  2.1 0.178
Triglycerides (mg/dl) 26.5  14.8 5.8  10.2 0.074 17.8  10.4 0.015
Data are n (%) or change in least-squares means  SE unless otherwise indicated. *HOMA-B, homeostasis model of assessment of -cell function.
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